Research Paper Volume 13, Issue 20 pp 23810—23830

CCR5 is a prognostic biomarker and an immune regulator for triple negative breast cancer


Figure 7. Kaplan-Meier analyses indicate that patients in low risk group have better OS than those in high risk group (blue represents low risk group and yellow represents high risk group, Logrank p < 0.0001).